Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. First-Line Avelumab Plus Axitinib Is Not Cost-Effective vs Sunitinib for Advanced RCC
  2. ASCO: Nivolumab Followed by Salvage Ipilimumab Plus Nivolumab for Patients With Advanced Renal Cell Carcinoma
  3. ASCO: Lenvatinib Plus Pembrolizumab After Progression on Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma
  4. Contemporary Age-Adjusted Incidence and Mortality Rates of RCC
  5. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma
  6. Bone Metastasis Is Associated With Poor Prognosis in Metastatic Papillary RCC Treated With First-Agent Angiogenesis Inhibitors
  7. Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell RCC
  8. Earlier Development of IRAEs Is Associated With Poor Clinical Outcome in mRCC Patients Treated With Nivolumab
  9. ASCO 2020: Abstract Recommendations From Dr. Jun Gong for Gastrointestinal Cancer
  10. ASCO 2020: Abstract Recommendations From Dr. Jun Gong for Genitourinary Cancer

Elsewhere

Recently Updated